In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback